Close Menu

Mobidiag

The company already offers an antibody test, Anti-SARS-CoV-2 Rapid Test, that it is distributing for its Chinese joint venture partner Autobio Diagnostics.

The Novodiag COVID-19 real-time PCR assay enables on-demand and fully automated detection of early COVID-19 infections in about one hour, the firm said.

Use of the assay by Finland's main clinical laboratories will double testing capacity and allow test coverage for most of the country, Mobidiag said.

A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.

The new funding supports development of a rapid molecular test to detect bloodstream infections directly from whole blood.

Mobidiag signed agreements for its Amplidiag and Novodiag products with Alab in Poland and the Ukraine; Biogenetix in Romania; and Theranostica in Israel.

The firm said that its newly CE-marked test for intestinal infections is suitable for use in laboratories and hospitals, and provides results in 90 minutes.

The firm's CEO said it is continuing to develop its distributor network to make its tests available in centralized and decentralized settings globally.

Dubbed Automobi Molecular Diagnostics, the company will establish local manufacturing facilities and work to commercialize the Novodiag platform in China.

The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.